Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.
- Citation data:
Bone, ISSN: 1873-2763, Vol: 105, Page: 11-17
- Publication Year:
- Medicine; Biochemistry, Genetics and Molecular Biology
- Most Recent Tweet View All Tweets
The optimal duration of osteoporosis treatment is controversial. As opposed to bisphosphonates, denosumab does not incorporate into bone matrix and bone turnover is not suppressed after its cessation. Recent reports imply that denosumab discontinuation may lead to an increased risk of multiple vertebral fractures.